Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: An analysis of the TREAT (trial to reduce cardiovascular events with aranesp therapy) placebo arm

Hicham Skali, Julie Lin, Marc A. Pfeffer, Chao Yin Chen, Mark E. Cooper, John J V McMurray, Allen R. Nissenson, Giuseppe Remuzzi, Jerome Rossert, Patrick S. Parfrey, Nairne W. Scott-Douglas, Ajay K. Singh, Robert Toto, Hajime Uno, Peter Ivanovich

Research output: Contribution to journalArticle

Abstract

Background: Sparse data are available about the natural history of hemoglobin (Hb) level trends in contemporary patients with anemia, chronic kidney disease (CKD), and type 2 diabetes mellitus. We intended to describe Hb level trends over time with no or minimal administration of erythropoiesis- stimulating agents. Study Design: Prospective clinical trial cohort. Setting & Participants: 2,019 individuals with type 2 diabetes, moderate anemia, and CKD from the placebo arm of the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) followed up for 2.3 years with an average of 32 monthly Hb level determinations per patient. Darbepoetin alfa was administered only if Hb level decreased to

Original languageEnglish
Pages (from-to)238-246
Number of pages9
JournalAmerican Journal of Kidney Diseases
Volume61
Issue number2
DOIs
Publication statusPublished - Feb 2013

Keywords

  • Anemia
  • erythropoiesis-stimulating agents
  • placebo

ASJC Scopus subject areas

  • Nephrology

Fingerprint Dive into the research topics of 'Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: An analysis of the TREAT (trial to reduce cardiovascular events with aranesp therapy) placebo arm'. Together they form a unique fingerprint.

  • Cite this

    Skali, H., Lin, J., Pfeffer, M. A., Chen, C. Y., Cooper, M. E., McMurray, J. J. V., Nissenson, A. R., Remuzzi, G., Rossert, J., Parfrey, P. S., Scott-Douglas, N. W., Singh, A. K., Toto, R., Uno, H., & Ivanovich, P. (2013). Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: An analysis of the TREAT (trial to reduce cardiovascular events with aranesp therapy) placebo arm. American Journal of Kidney Diseases, 61(2), 238-246. https://doi.org/10.1053/j.ajkd.2012.08.043